Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep499 | Diabetes (complications & therapy) | ECE2015

Effect of gemigliptin switching from pioglitazone with metformin in type 2 diabetes

Kim Yonghyun , Shin Donghyun

The DPP4 inhibitors that increase insulin secretion by glucose dependently can also relieve insulin resistance because they improve early phage insulin secretion and prevent late hyperinsulinaemia. It also can be more effective in controlling the blood glucose because it acts synergistically with metformin by improving insulin secretory dysfunction compared TZD with metformin that has similar action mechanism. One of those is gemigliptin that was developed in this country rece...

ea0035p493 | Diabetes therapy | ECE2014

Effect of omega-3 polyunsaturated fatty acids on insulin resistance in type 2 diabetes

Kim Yonghyun , Shin Donghyun

Background: Omega-3 polyunsaturated fatty acids are found in fish oil and they have been shown to mitigate the risk of cardiovascular disease. The mechanisms of which are not only improvement of triglycerides and various lipid parameters, but also beneficial effects on arrhythmia, inflammation. There are animal experimental results that omega-3 fatty acid can improve insulin resistance related to obesity and non-alcoholic steatohepatitis. The mechanism can be activation of PPA...

ea0032p480 | Diabetes | ECE2013

The long term effect of metformin plus DPP-4 inhibitor switching from metformin plus pioglitazone combination therapy in type 2 diabetes

Kim Yonghyun , Shin Donghyun

Two years ago, we presented the short term 6 month results of metformin plus DPP-4 inhibitor combination therapy when we can’t reach the target below 7% of HgA1c with metformin plus pioglitazone combination that is best in terms of relieving insulin resistance in early diabetes.Switching the pioglitazone to the DPP-4 inhibitor that improves insulin secretory dysfunction can be the next useful step to attain glucose control goal and DPP-4 inhibitors ...

ea0063p220 | Diabetes, Obesity and Metabolism 1 | ECE2019

The effect of dapagliflozin add on to triple combination therapy in Type 2 diabetes

Kim Yonghyun , Shin Donghyun , Lee Seongkyeong

Before releasing of SGLT-2 inhibitor, triple combination of metformin, DPP-4 inhibitor and TZD except sulfonylurea was commonly used in our center because it could be best option for delaying progression of diabetes by improving both insulin resistance and secretory dysfunction. SGLT-2 inhibitor is commonly used and recommended as initial combination with metformin in most guidelines because of cardiovascular risk and weight reduction, but theoretically add on to above combina...

ea0049ep1256 | Thyroid (non-cancer) | ECE2017

Clinical characteristics of painless thyroiditis

Kim Yonghyun , Choi Jeonga , Shin Donghyun

Background: There are a lot of painless thyroiditis cases without symptoms diagnosed on health check up or thyroid hormone screening, but there is a few data about it compared to much data about painful subacute thyroiditis. So, we collected data about diagnostic routes, laboratory and clinical characteristics of painless thyroiditis.Method: Painless thyroiditis patients diagnosed between 2010 and 2016 were reviewed. We defined painless thyroiditis as di...

ea0026p677 | Diabetes therapy | ECE2011

Comparative study of combination therapy between metformin plus thiazolinedione (TZD) and metformin plus DPP-4 inhibitor in type 2 diabetes

Kim Yonghyun , Shin Donghyun , Lee Eunjong

The pathogenesis of type 2 diabetes is explained by increment of insulin resistance and dysfunction of insulin secretion. If improvement of insulin resistance is not adequate in the early stage of diabetes especially in this country with more severe basal insulin secretion defect from the very beginning, diabetes rapidly progress to more aggressive stage with relative insulin deficiency. The most proper method of improving insulin resistance by prescription is metformin from t...